Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
Tony Mok(Chinese University of Hong Kong), Lin Wu(Materials Systems (United States)), Julie Tsai(Materials Systems (United States)), Jennifer Sandoval-Tan(Philippine General Hospital), Caicun Zhou(Tongji University), David S. Shames(Gene Therapy Laboratory), Fatima Fuerte(University of Asia and the Pacific), Barbara Klughammer(Roche (Switzerland)), Vichien Srimuninnimit(Siriraj Hospital), Wei Wen(Materials Systems (United States)), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Jin Soo Lee(Inha University), Virote Sriuranpong(Chinese University of Hong Kong), Yunzhong Zhu(Beijing Chest Hospital), Meilin Liao(Shanghai Chest Hospital), Benjamin Margono(Universitas Dr. Soetomo), Sumitra Thongprasert(Chiang Mai University), Guia Ladrera(University of the Philippines System), Chong‐Jen Yu(National Taiwan University Hospital)
Cited by 469
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k